Cardiotoxicity of azithromycin in COVID-19: an overall proportion meta-analysis.

Ioannis T FarmakisIoanna MinopoulouGeorge GiannakoulasAfroditi Boutou

Published in: Advances in respiratory medicine (2022)

Azithromycin, with or without hydroxychloroquine, leads to a significant risk for critical QTc prolongation in patients with Covid19. Due to its cardiotoxicity effects and its unproven efficacy in Covid19, azithromycin use should be limited to cases of bacterial co-infection.

Keyphrases

coronavirus disease
sars cov
systematic review
meta analyses
respiratory syndrome coronavirus
randomized controlled trial
drug induced